Attend our symposium and poster presentations at the ISPOR 20th Annual European Congress, 4 – 8 November, 2017. Connect with Cardinal Health Specialty Solutions on the exhibit floor at Booth #811.

 

Poster Presentations

Multiple posters evaluating real-world evidence (RWE) and health resource utilization in oncology and rheumatology, including uptake of new and novel agents and unmet needs in treatment for rare cancers.

Educational Symposium

Monday, 6 November 2017, 7:30-8:30 am

Real-World Evidence to Support Regulatory Approvals Based on Tumor Biomarkers in Oncology Research

In a historic first, the U.S. Food and Drug Administration (FDA) recently approved a cancer treatment based on a common biomarker rather than histologic tumor origin.

This paradigm-changing approval is at the intersection of precision medicine and immuno-oncology and creates unique challenges for all stakeholders: What demands will be placed on health economists to analyze smaller and smaller patient populations? How will these analyses be conducted in patients with highly variable clinical scenarios whose only commonality is a shared actionable mutation? What information will patients, providers, and payers need to become comfortable in this new reality?

Key stakeholders to weigh in on a robust discussion that includes real-world evidence (RWE) beyond claims and medical records, prospective outcomes research beyond registries, linking patient-reported outcomes to clinical outcomes, and how RWE research studies can be designed to effectively capture the required clinical biomarker data to support such approvals in future.

Missed us in Boston?

View the Cardinal Health educational symposium from the June 2017 ISPOR 22nd Annual International Meeting in Boston, focused on Health Economics and Outcomes Research (HEOR) in the Era of Value-Based Care and the 21st Century Cures Act »